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Abstract. Background/Aim: Breast cancer is the most
common type of cancer among women. Breast infiltrating
ductal carcinoma (IDC) is the most common type of breast
cancer, approximately 80% of all breast carcinomas. The aim
of this study was to analyze the association of tumor size,
evaluated after histopathological analysis, with different
clinical and biological parameters in IDC. Materials and
Methods: The study group included 251 women with IDC
without axillary lymph node involvement, aged between 27
and 81 years. Analyzed parameters were: age, histological
grade, menopausal status, menarche, pregnancy, abortion,
breastfeeding, contraceptive use, hormone replacement
therapy, estrogen receptor (ER), progesterone receptor (PR),
androgen receptor (AR), Ki-67, p53 and BCL2. Results:
Pathological tumor size was between 0.2 and 5.1 cm
(1.43±0.86 cm). Tumors in 45 cases exceeded 2 cm, in eight
3 cm and only in one 5 cm. Pathological size was
significantly associated with age >70 vs. <50 years
(p=0.054), histological grade III vs. I (p=0.0003), positivity
for Ki-67 (p=0.0003) and for p53 (p=0.0032). Conclusion:
Tumor size was significantly associated with age >70 years,
histological grade 3 and immunohistochemically-augmented
expression of Ki-67 and p53.
Breast cancer is the most common type of cancer among
women, accounting for 23% of the total cancer cases and 14%
of the cancer-related deaths worldwide (1). Breast infiltrating
ductal carcinoma (IDC) is the most common type of breast
cancer. About 80% of all breast carcinomas are IDCs.
Tumor size is an important parameter in the biology of
malignant tumors. In this regard, we know that tumors
detected during screening and the luminal A subtype usually
have a smaller size (2, 3), whilst conversely, the triple-
negative subtype have a larger size (4). Size is associated with
axillary lymph node involvement and distant spread, setting
the classic prognostic TNM classification. Histological grade,
lymphovascular invasion and hormone receptors status are
also important prognostic factors (5-7). In young women,
prognostic value is found to be associated with the axillary
and molecular subtype, whereas in patients without axillary
lymph node involvement, the only prognostic factor was the
molecular subtype (8). 
Among patients with node-negative disease, increasing
tumor size has been associated with increased breast
cancer-specific mortality. In addition, increasing tumor size
has been correlated with a higher risk of axillary lymph
node involvement. Although larger tumor size and
increasing lymph node involvement have traditionally been
considered independent predictors of higher mortality,
tumors which metastasize to lymph nodes early in the
disease process (at a small tumor size) may reflect a more
biologically-aggressive phenotype, and thus a smaller
tumor size may paradoxically be associated with a higher
risk of distant spread (9).
Endocrinologically, it is noteworthy that an increase of
body-mass index (BMI) and dehydroepiandrosterone sulfate
(DHEAS) levels have been associated with larger tumors by
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partial correlation, whereas higher androstenedione levels
corresponded with smaller tumors (10). Numerous imaging
techniques have been used to define tumor size, with no total
agreement about its practical usefulness (11, 12), although
the recent introduction of breast tomosynthesis appears to be
the most effective technique (13, 14).
Less well-known is the association between tumor size
and tissue-based tumor markers, including hormone
receptors, and new prognostic factors such as p53, BCL2 or
Ki-67. These are tumor markers frequently expressed in
breast cancer (16, 17).
The aim of this work was to analyze tumor size in patients
with IDC without axillary lymph node involvement, in
relation to: i) clinicopathological parameters, ii) hormonal
receptors and iii) tissue-based tumor markers.
Materials and Methods
Patients. Two hundred and fifty-one women affected by breast IDC
without axillary lymph node involvement, aged between 27 and 81
years (mean age=60.1±8.4 years, median 60 years) who had
undergone no prior treatment were studied at the Breast Unit at the
Monte del Naranco Hospital, Oviedo, Spain. They were selected
from a breast cancer screening program from 2000 to 2007. All
patients signed informed consent for the sampling and analysis of
their tissue for research purposes.
Methods. Pathological tumor size was considered between 0.2 and 5.1
cm (mean size=1.43±0.86 cm; median=1.3 cm). Parameters analyzed
were: age, histological grade, menopausal status, menarche, pregnancy,
abortion, breastfeeding, contraceptive use, anticonception, hormone
replacement therapy (HRT). We also considered immunohistochemical
expression of estrogen receptor (ER), progesterone receptor (PR),
androgen receptor (AR), Ki-67, p53 and BCL2.
Immunohistochemical staining of tissue sections of 4-5
microns was performed by the EnVision method with a heat-
induced antigen retrieval step. Sections were immersed in boiling
10 mmol/l sodium citrate at pH 6.5 for 2 min in a pressure
cooker. ER and PR were determined using monoclonal antibodies
to ER and PR phramDx (clones 1D5 and ER-2123 respectively),
1294 for the PR, p53 (DO-7, dilution 1/50; Dako), Ki-67 (MIB-
1, dilution 1/200; Dako), BCL2 (Biogenex, dilution 1/150) and
androgen receptor (AR441, dilution 1/150; Dako) were used in
this study. ER and PR were assessed according to the Allred
score as negative (scores 0-2) and positive (score 3-8), and
positivity thresholds for p53 and Ki-67 were 20% and 15% ,
respectively. AR was classified as positive or negative without
any score, and BCL2 as negative (–), weakly positive (+) and
strongly positive (+ +).
The Windows SPSS software was employed for statistical
analysis. Continuous variables with a normal Gaussian distribution
are expressed as the mean and standard deviation, while non-
parametric variables are expressed by the range and median. We
used the Chi-square test with Yates correction, if necessary, for
comparison of qualitative variables, and Mann Whitney test for
continuous ones. The criteria on for differences to be considered as
significant was p<0.05.
Results
In the study group analyzed, pathological tumor size ranged
from 0.2 to 5.1 cm (1.43±0.86 cm). Tumors in 45 cases
exceeded 2 cm; in eight, 3 cm and only in one, 5 cm.
Table I shows tumor size according to the clinicopathological
parameters analyzed. Pathological size was significantly
associated with age >70 vs. <50 years (p=0.054), and
histological grade III vs. I (p=0.0003).
Table II shows the relationship between tumor size and the
tissue-based tumor markers analyzed. There were significant
differences for Ki-67 (p=0.001) and p53 positivity
(p=0.006). 
Table III shows the relationship between tumor size and
the hormonal receptors analyzed. There were no significant
differences when the expression of ER, PR and AR were
considered.
Discussion
Tumor size is a classical parameter of tumor biology and is
directly related to a greater chance for regional axillary
involvement, a greater number of invaded nodes and greater
probability of recurrence and death. Its prognostic value can
be seen in cases with and without axillary lymph node
involvement, being very important in the absence of regional
spread because it may help identify patients with high or low
risk of recurrence (15-17). 
The Surveillance, Epidemiology and End Results (SEER)
database included 13,464 women with node-negative breast
cancer and patients with tumors less than 1 cm which had a
5-year overall survival (OS) close to 99%, compared to 89%
for those with tumors between 1 and 3 cm and 86% for
tumors between 3 and 5 cm (18). This association persists
with longer follow-up. Rosen et al. examined the relationship
between tumor size and 20-year recurrence-free survival and
found a significant association, with a 20-year recurrence-
free survival of 88% for these with tumors ≤1 cm, 72% for
those with tumors 1.1 to 3 cm, and 59% for those with
tumors between 3.1 and 5 cm (19). Furthermore, the median
time-to-development of metastatic disease also shortens
when tumor size increases (20, 21). 
The more remarkable fact, from a practical point of view,
is the relationship between tumor size and axillary lymph
node involvement, so both determine different survival. Size
is an important prognostic factor, especially in N0 cases,
with differences between pT1a-b and pT1c (14). Size was a
poor prognostic factor of tumors with HER2/ERBB2
overexpression (22). It is interesting to note that the size of a
contralateral tumor is associated with the size of the primary
tumor (23). Many relationships have been described between
tumor size and different clinical and biological factors,
including: BAX, cathepsin D, aneuploidy, Ki-67,
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cyclooxygenase 2, mean nuclear area, FOXP3 and
immunosuppressive regulatory T-cells. No relation with
lymphovascular invasion (FDG), cell-regulatory proteins,
matrix metalloproteinases, mammaglobin, hTERT, Wilms
gene, tumor vascularity, vimentine, mitotic figure counts and
apolipoprotein D has been described. In relation to ERBB2,
described results are inconsistent (23).
In the present study, we analyzed possible associations
between tumor size and clinicobiological factors commonly
used in daily clinical practice in patients with breast IDCs
without axillary lymph node involvement, that is, focusing
exclusively on the size. Following analysis of 251 cases, a
statistically significant association was found between tumor
size and age over 70 years, advanced histological grade, high
cell proliferation and immunohistochemical expression of
p53. With regards to age, we found larger tumor sizes in
women over 70 years, of borderline statistical significance,
a finding also described by other authors (24). In a previous
study, we found that women older than 70 years had an
increased tumor size when were from a hospital breast unit,
but not if they were from screening campaigns, and this was
also confirmed in women between 60 and 70 years, which
highlights the importance of the patient’s origin and supports
the possible cause of greater tumor size being a delayed
diagnosis (25). 
We found larger tumors with histological grade 3, a fact
consistent with that described by other authors (26, 27).
Histological grade is a classic parameter of breast tumor
biology and is associated with survival and TNM
classification (15, 28-30), being of particular relevance in
cases without axillary lymph node involvement, which
allows patients to be stratified for certain therapies (26).
Although histological grade has long been considered a
prognostic factor in breast cancer, it was not included in the
American Joint Committee on Cancer (AJCC) staging
criteria (31). We note, in addition, an association between
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Table I. Relationship between tumor size and clinicopathological
parameters. A p-value of 0.05 was considered to be significant.
Tumor size (cm)
n Range Mean±SD Median p-Value
Age
<50 years 32 0.2-3.5 1.6±0.8 1.5 0.054
>70 years 48 0.7-1.3 2.4±1.3 2.0
HG
I 71 0.4-4.3 1.2±0.6 1.0 <0.001
III 61 0.3-3.4 1.5±0.7 1.5
Menarche
<14 years 154 0.3-8.0 1.5±0.9 1.4 ns
≥14 years 97 0.3-6.0 1.6±1.0 1.4
Menopause
Pre-menopausal 33 0.2-8.0 1.2±0.7 1.2 ns
Post-menopausal 212 0.3-8.0 1.5±0.9 1.3
Pregnancy
Yes 205 0.3-8.0 1.4±0.9 1.3 ns     
No 46 0.2-4.3 1.3±0.8 1.2
Abortion
Yes 42 0.4-5.0 1.4±0.9 1.2 ns
No 209 0.2-8.0 1.4±0.0 1.3
Lactating
Yes 162 0.3-8.0 1.4±0.9 1.4 ns
No 89 0.3-4.3 1.5±0.8 1.3
Contraceptive use
Yes 13 0.6-15 1.2±0.3 1.2 ns
No 238 0.2-8.0 1.4±0.9 1.3
HRT
Yes 25 0.5-8.0 1.5±1.5 1.2 ns
No 226 0.2-5.0 1.4±0.8 1.3
HG: Histological grade; HRT: hormone replacement therapy.
Table III. Relationship between tumor size and and hormonal receptor
expression. A p-value of 0.05 was considered to be significant.
Tumor size (cm)
n Range Mean±SD Median p-Value
ER
– 38 0.3-4.0 1.5±0.9 1.3 ns
+ 213 0.3-5.0 1.4±0.8 1.3
PR
– 108 0.2-5.0 1.4±0.9 1.3 ns
+ 143 0.3-4.3 1.4±0.8 1.3
AR
– 90 0.2-4.0 1.6±0.9 1.4 ns
+++ 161 0.3-5.5 1.4±0.9 1.3
ER: Estrogen receptor, PR: progesterone receptor, AR: androgen
receptor.
Table II. Relationship between tumor size and and tissue-based tumor
markers. A p-value of 0.05 was considered to be significant.
Tumor size (cm)
n Range Mean±SD Median p-Value
Ki67 
– 126 0.4-8.0 1.4±0.9 1.2 0.001
+ 125 0.2-4.0 1.5±0.7 1.4
p53 
– 205 0.3-8.0 1.4±0.9 1.2 0.006
+ 46 0.2-4.0 1.6±0.8 1.6
BCL2 
– 94 0.3-4.0 1.5±0.9 1.2 ns
++ 157 0.4-8.0 1.5±0.9 1.3
increased tumor size and immunohistochemical expression
of Ki-67 and p53. 
Cell proliferation is a prognostic factor in cases without
axillary lymph node involvement (32) and correlates with
various biological factors, including p53. Recently,
Silvestrini et al. demonstrated that tumor cell proliferation is
an important predictor of axillary relapse in elderly patients
with ER-positive breast cancer and could help to identify
patients who should undergo axillary surgery (33).
Association between larger tumor size and p53 has been
described by others, but not by Temmin et al. (34) and Al
Joudi et al. (35), who found that this behaves as a prognostic
factor for some groups. As for histological grade, it could be
useful to distinguish risk subgroups in cases without axillary
lymph node involvement. By itself, it is useful in T2N0
cases, but not inT1N0 cases (36).
Tumor size is, therefore, associated with certain clinical
and biological factors which, at the same time, relate to each
other and several other factors that determine a more
undifferentiated and aggressive phenotype such as
lymphovascular invasion, aneuploidy and loss of hormone-
dependence (27). 
Conclusion
These results led us to the following conclusion: in breast
IDCs without axillary lymph node involvement, tumor size
was significantly associated exclusively with age over 70
years, histological grade 3 and increased immunohisto-
chemical expression of Ki-67 and p53, all of which support
its prognostic value.
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